Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -3.7M | 5.1% |
| Cost of Revenue | 3.7M | 21.7% |
| Operating expense | 16M | 10.4% |
| Net Income | -15M | 10.3% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 117M | 6.9% |
| Total Liabilities | 32M | 16.2% |
| Total Equity | 85M | 13.4% |
| Shares Outstanding | 60M | 0.2% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -8M | 39.7% |
| Cash from investing | 5.3M | 128.9% |
| Cash from financing | -200,000 | 0% |
EPS
Financial Highlights for Aldeyra Therapeutics in Q3 '24
Gross Profit stood at -3.7M, marking a -5.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.7M, a 21.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 16M, showing a -10.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -15M, showing a 10.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Aldeyra Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
